BCAL Diagnostics Limited (BDX.AX)
AUD 0.09
(-2.17%)
AUD 0.09
(-2.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 641.34 Thousand AUD | 43.57% |
| 2023 | 1.06 Million AUD | 0.0% |
| 2022 | - AUD | 0.0% |
| 2021 | - AUD | -100.0% |
| 2020 | 300 Thousand AUD | 0.0% |
| 2019 | - AUD | -100.0% |
| 2018 | 500 Thousand AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 FY | 1.52 Million AUD | 43.57% |
| 2024 Q1 | 1.32 Million AUD | 25.16% |
| 2024 Q3 | 641.34 Thousand AUD | -57.32% |
| 2024 Q4 | 641.34 Thousand AUD | 137.6% |
| 2024 Q2 | 1.5 Million AUD | 13.12% |
| 2023 Q3 | 896.79 Thousand AUD | 0.0% |
| 2023 FY | 1.06 Million AUD | 0.0% |
| 2023 Q4 | 1.06 Million AUD | 18.35% |
| 2023 Q1 | - AUD | 0.0% |
| 2023 Q2 | - AUD | 0.0% |
| 2022 Q1 | - AUD | 0.0% |
| 2022 FY | - AUD | 0.0% |
| 2022 Q4 | - AUD | 0.0% |
| 2022 Q3 | - AUD | 0.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2021 Q3 | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2021 Q1 | - AUD | -100.0% |
| 2021 FY | - AUD | -100.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2020 FY | 300 Thousand AUD | 0.0% |
| 2020 Q4 | 300 Thousand AUD | 0.0% |
| 2020 Q3 | 300 Thousand AUD | 0.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2019 FY | - AUD | -100.0% |
| 2018 FY | 500 Thousand AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Australian Clinical Labs Limited | 308.89 Million AUD | 99.792% |
| Genetic Signatures Limited | 1.22 Million AUD | 47.474% |
| Genetic Technologies Limited | 643.54 Thousand AUD | 0.343% |
| Healius Limited | 1.59 Billion AUD | 99.96% |
| Imagion Biosystems Limited | 6.03 Million AUD | 89.379% |
| Integral Diagnostics Limited | 357.79 Million AUD | 99.821% |
| INOVIQ Ltd | 535.05 Thousand AUD | -19.863% |
| Microba Life Sciences Limited | 395.38 Thousand AUD | -62.206% |
| Monash IVF Group Limited | 59.56 Million AUD | 98.923% |
| Rhythm Biosciences Limited | 163.82 Thousand AUD | -291.486% |
| Sonic Healthcare Limited | 4.51 Billion AUD | 99.986% |